CJChristina S. Jacobsen

Christina S. Jacobsen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Christina S. Jacobsen has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Immune signature of Chlamydia vaccine CTH522/CAF®01 translates from mouse-to-human and induces durable protection in mice

    by Anja W. Olsen, Ida Rosenkrands, Christina S. Jacobsen, Hannah M. Cheeseman, Max P. Kristiansen, Jes Dietrich, Robin J. Shattock, Frank Follmann

    The clinical development of an effective Chlamydia vaccine requires in-depth understanding of how well protective pre-clinical immune signatures translate to humans. Here, we report a comparative immunological characterization of CTH522/CAF®01 in female mice and humans. We find a range of immune signatures that translate from mouse to human, including a Th1/Th17 cytokine profile and antibody functionality. We identify vaccine-induced T cell epitopes, conserved among Chlamydia serovars, and previously found in infected individuals. Using the mouse model, we show that the common immune signature protected against ascending infection in mice, and vaccine induced antibodies could delay bacterial ascension to the oviduct, as well as development of pathology, in a T cell depleted mouse model. Finally, we demonstrate long-lasting immunity and protection of mice one year after vaccination. Based on the results obtained in the present study, we propose to further investigate CTH522/CAF®01 in a phase IIb study.


  • Open Access

    Immune signature of the Chlamydia vaccine CTH522/CAF®01 translates from mouse to human and induces durable protection

    by Anja Olsen, Ida Rosenkrands, Christina Jacobsen, Hannah Cheeseman, Max Kristiansen, Jes Dietrich, Robin Shattock, Frank Follmann

    The clinical development of an effective Chlamydia vaccine requires in-depth understanding of how well protective pre-clinical immune signatures translate to humans. Here we report the first comparative immunological characterization of CTH522/CAF®01 in mice and humans. We find a range of immune signatures that translate from mouse to humans, including a Th1/Th17 cytokine profile and antibody functionality. Interestingly, we identified vaccine-induced T cell epitopes, conserved among serovars and previously found in infected individuals. Using the mouse model, we show that the common immune signature protected against ascending infection in mice and vaccine induced antibodies could delay bacterial ascension to the oviduct, as well as development of pathology, in a T cell depleted mouse model. Finally, we demonstrate long-lasting immunity and protection of mice one year after vaccination. Based on the results obtained in the present study, we propose to further investigate CTH522/CAF®01 in a phase IIb study.